Bayer AG (BAYGn.DE)

EU watchdog backs Bayer acne drug for certain patients

Bayer to acquire herbal medicine maker Steigerwald

FRANKFURT, May 16 - Germany's largest drugmaker Bayer said it agreed to buy privately held Steigerwald Arzneimittelwerk GmbH, a maker of herbal treatments.

Bayer, Algeta win FDA approval for prostate cancer drug

FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

Bayer's plastics chief sees room to raise prices

LEVERKUSEN, Germany - Bayer suggested there was room to lift prices at its high-tech plastics and chemicals business this year to counter soaring raw material costs that squeezed first quarter margins.

Court tells Bayer to compensate Schering shareholders

FRANKFURT, May 6 - A court ruled that Bayer did not pay some former Schering shareholders enough to acquire its German rival in 2007 and must now pay them more than 300 million euros ($392 million) in compensation, lawyers for the shareholders said.

Bayer stops drug trial with haemophilia drug BAY 86-6150

FRANKFURT, May 3 - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

Bayer to buy birth-control devices maker for $1.1 billion

FRANKFURT - Germany's Bayer AG has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider,

UPDATE 1-Bayer to buy birth-control devices maker for $1.1 bln

* Purchase of Concetpus is latest in string of bolt-on deals

CORRECTED-Bayer plans to buy Conceptus for $1.1 bln

FRANKFURT, April 29 - Germany's Bayer agreed to acquire U.S. birth-control devices company Conceptus for $1.1 billion in cash, to cement its position as the world's largest women's healthcare provider.

Bayer cuts plastics outlook, as higher costs hurt

FRANKFURT - Weak demand for Bayer's plastics and chemicals forced the diversified healthcare group to lower its outlook for its MaterialScience division, marring earnings gains at its farming pesticides unit.